Intuitive Surgical, Inc. vs MiniMed Group Inc. Common Stock — how do they compare? Intuitive Surgical, Inc. trades at $423.23 (market cap $146.76B), while MiniMed Group Inc. Common Stock trades at $19.53 (market cap $5.57B). The key difference: Intuitive Surgical, Inc. is far larger — about 26.3× MiniMed Group Inc. Common Stock's market cap, and MiniMed Group Inc. Common Stock is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and MiniMed Group Inc. Common Stock for 0 Days on average.
| ISRG | MMED | |
|---|---|---|
Market Cap | $146.76B | $5.57B |
Volume | 2,529,814 | 23,336,073 |
Sector | Health | Health |
52-Week High | $592.85 | $23.84 |
52-Week Low | $332.02 | $10.80 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $141.54B | $5.37B |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $414.52, up 2.41% today, with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with revenue growth from $6.2B in 2022 to $10.1B in 2025 and net income margin expanding to 28.45%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.80 surpassing the $2.48 forecast.
ISRG maintains a dominant position in robotic surgery with expanding international growth, though valuation multiples remain elevated with a P/E of 47.64. Analyst consensus is strongly bullish with a $480.78 price target representing 16% upside potential. Key risks include competitive pressures and international market volatility, particularly in China.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →